Citadel Advisors’s CoLucid Pharmaceuticals, Inc. CLCD Stock Holding History

Citadel Advisors’s Portfolio CLCD Stock Details CLCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-704,458	Closed	-$25.6M	–	8491
2016 Q4	$25.6M	Buy	704,458 +626,751	+807%	+$22.2M	0.03%	704
2016 Q3	$2.96M	Buy	+77,707	New	+$1.15M	﹤0.01%	2509

Other funds holding CLCD

FPF

FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Citadel Advisors's CLCD Position: Q1 2017 in Review

Citadel Advisors sold out of CoLucid Pharmaceuticals, Inc. (CLCD) in Q1 2017, closing a stake of 704,458 shares — an estimated $25.6M sold.

Citadel Advisors first reported a position in CLCD in Q3 2016 and held it in 2 quarters. The position peaked at $25.6M in Q4 2016. 1 fund tracked by Wall St. Rank holds CLCD as of Q1 2017.

Citadel Advisors reported no remaining CoLucid Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Citadel Advisors sold 704,458 CoLucid Pharmaceuticals, Inc. shares in Q1 2017, an estimated $25.6M.
Citadel Advisors first reported a position in CoLucid Pharmaceuticals, Inc. in Q3 2016 and held it in 2 quarters.
Citadel Advisors's CoLucid Pharmaceuticals, Inc. position peaked at $25.6M in Q4 2016.
1 fund tracked by Wall St. Rank held CoLucid Pharmaceuticals, Inc. as of Q1 2017.

Based on Citadel Advisors's 13F filing for Q1 2017, filed 12 May 2017.